Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Fludarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | CA5A | P35218 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine SCHEMBL6342036 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL31010885 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL28482317 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL31010884 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL2732720 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL21465082 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL13046076 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL12018219 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL12232219 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL13046078 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34804 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026102321-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | MARO BIO INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| US-20260090997-A1 | Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods | UNIV EMORY (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| EP-0770143-A1 | METHOD TO IDENTIFY TUMOR SUPPRESSOR GENES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-05-02 | — | — | EP | claimed |
| EP-0769967-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND DIAGNOSTIC DEVICE COMPRISING SAME AND THEIR USE | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 1997-05-02 | — | — | EP | claimed |
| WO-1996005863-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND DIAGNOSTIC DEVICE COMPRISING SAME AND THEIR USE | LA REGION WALLONNE (BE) | 1996-02-29 | — | — | WO | claimed |
| WO-1995034680-A1 | METHOD TO IDENTIFY TUMOR SUPPRESSOR GENES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1995-12-21 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| WO-1992009604-A1 | 6-AZIDO-2-FLUOROPURINE | BERLEX BIOSCIENCES, INC. (US) | 1992-06-11 | — | — | WO | claimed |
| US-5081110-A | Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-01-14 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |